Compass Therapeutics, Inc. Stock OTC Markets
Stocks
CMPX
US20454B1044
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.015 USD | -43.24% |
|
+32.67% | - |
| Market Cap | 369M 318M 293M 276M 518M 34.84B 522M 3.47B 1.35B 17.1B 1.39B 1.36B 59.15B | P/E 2026 * |
-4.68x | P/E 2027 * | -4.41x |
|---|---|---|---|---|---|
| Enterprise Value | 219M 189M 174M 164M 307M 20.68B 310M 2.06B 802M 10.15B 823M 805M 35.12B | EV / Sales 2026 * |
-98.9x | EV / Sales 2027 * | 9.24x |
| Free-Float |
87.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Compass Therapeutics, Inc.
| 1 day | -43.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Thomas Schuetz
CEO | Chief Executive Officer | 65 | 2024-05-27 |
Barry Shin
DFI | Director of Finance/CFO | 54 | 2024-12-08 |
Cynthia Sirard
CTO | Chief Tech/Sci/R&D Officer | 56 | 2025-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Schuetz
BRD | Director/Board Member | 65 | 2013-12-31 |
Phil Ferneau
BRD | Director/Board Member | 64 | 2014-12-31 |
Carl Gordon
CHM | Chairman | 61 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -43.24% | +32.67% | - | - | 369M | |
| -2.72% | -2.17% | +60.49% | +110.72% | 56.24B | |
| +0.04% | +1.20% | +47.67% | +36.75% | 43.76B | |
| -2.17% | +0.68% | -13.65% | -18.00% | 23.32B | |
| -2.10% | -0.39% | -3.14% | +376.69% | 21.34B | |
| +3.22% | +2.94% | +24.02% | -34.00% | 15.75B | |
| -0.67% | +0.56% | +14.75% | -38.47% | 15.6B | |
| -2.42% | -4.54% | +25.36% | +169.64% | 13.18B | |
| +3.07% | +5.43% | +21.37% | - | 12.01B | |
| +1.92% | +2.43% | +112.68% | +232.59% | 11.87B | |
| Average | -4.50% | +3.15% | +32.17% | +104.49% | 23.68B | |
| Weighted average by Cap. | -0.91% | +2.96% | +35.86% | +96.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | -2.22M -1.91M -1.76M -1.65M -3.11M -209M -3.13M -20.82M -8.11M -103M -8.31M -8.14M -355M | 25.67M 22.15M 20.36M 19.17M 36.02M 2.42B 36.32M 241M 93.95M 1.19B 96.36M 94.3M 4.11B |
| Net income | -82.94M -71.55M -65.78M -61.92M -116M -7.83B -117M -780M -304M -3.84B -311M -305M -13.29B | -89.85M -77.51M -71.26M -67.08M -126M -8.48B -127M -845M -329M -4.16B -337M -330M -14.4B |
| Net Debt | -150M -129M -119M -112M -210M -14.16B -212M -1.41B -549M -6.95B -563M -551M -24.03B | -132M -114M -105M -98.54M -185M -12.46B -187M -1.24B -483M -6.11B -495M -485M -21.15B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CMPX Stock
- CMPX Stock
Select your edition
All financial news and data tailored to specific country editions
